Cardinal Health partnered with CDC to support vaccine access for pharmacies
On Nov. 11, 2020, Cardinal Health announced it had reached an agreement with the Centers for Disease Control…
-
-
Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine against SARS-CoV-2
On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…
-
COVID-19 immunity may last six months or more
On Nov. 11, 2020, Howard Hughes Medical Institute Investigator Michel Nussenzweig and his team reported that people who…
-
Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2
On Nov. 11, 2020, Sorrento Therapeutics announced that it was filing an investigational new drug application (IND) for…
-
Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
-
TB Quat Disinfectant Ready-to-Use Cleaner from 3M approved by EPA for use against SARS-CoV-2
On Nov. 10, 2020, 3M announced that its TB Quat Disinfectant Ready-to-Use Cleaner had been approved by the…
-
BD announced Canadian Government order of 76 million portable, rapid point-of-care antigen tests to detect SARS-CoV-2
On Nov. 10, 2020, BD (Becton, Dickinson) announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the…
-
Altimmune added Lonza as manufacturing partner for supply of AdCOVIDﾙ vaccine candidate for COVID-19
On Nov. 10, 2020, Altimmune announced an agreement with Lonza for the manufacturing of AdCOVIDﾙ, Altimmuneﾒs next-generation, single-dose…
-
Data showed SARS-CoV-2 reactive T Cells are associated with protection from COVID-19 was published
On Nov. 10, 2020, Oxford Immunotec announced the release of data from a prospective cohort study in keyworkers…
-
ImmunityBio, NantKwest announced positive interim phase 1 safety data of hAd5 COVID-19 vaccine dose study
On Nov. 10, 2020, ImmunityBio and NantKwest, a clinical-stage, natural killer cell-based therapeutics company, announced they had administered…
-
Medigen Vaccines and BlueWillow Biologics partnered to Develop intranasal vaccine for SARS-COV-2
On Nov. 19, 2020, Medigen Vaccine Biologics and BlueWillow Biologics announced a partnership to develop S-2P-NE-01, a nasal…
-
EUROIMMUN launched quantitative ELISA to measure SARS-CoV-2 antibodies against viral S1 protein
On Nov. 9, 2020, PerkinElmer announced that EUROIMMUN, a PerkinElmer company, had launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG)…
-
Biotechnology | HIV | NIH | Therapeutics
Long-acting injectable drug prevented HIV in cisgender women
On Nov. 9, 2020, the NIH reported that a pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form…
-
Ultragenyx announced plans to build large-scale gene therapy manufacturing facility for rare diseases
On Nov. 9, 2020, Ultragenyx announced that it planned to build a new large-scale gene therapy manufacturing facility…
-
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
On Nov. 9, 2020, a National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of…
-
Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 study
On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…
-
Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19
On Nov. 9, 2020, a study published in JAMA reported the effect of hydroxychloroquine on clinical status at…
-
Corvus completed enrollment in phase 1 study of CPI-006 for patients with COVID-19
On Nov. 9, 2020, Corvus Pharmaceuticals announced that it had completed patient enrollment in its Phase 1 study…
-
Fred Hutch began experimental COVID-19 vaccine efficacy trial
On Nov. 9, 2020, the Fred Hutchinson Cancer Research Center announced the start of volunteer enrollment for a…
-
Lilly’s neutralizing antibody bamlanivimab received FDA emergency use authorization for treatment of recently diagnosed COVID-19
On Nov. 9, 2020, the FDA granted Emergency Use Authorization (EUA) for Eli Lilly’s investigational neutralizing antibody bamlanivimab…
-
ImmunityBioﾒs hAd5 COVID-19 vaccine candidate stimulated memory T-Cell recall in patients with SARS-CoV-2
On Nov. 8, 2020, ImmunityBio announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which…
-
White-tailed deer found to be huge reservoir of SARS-CoV-2 infection
On Nov. 8, 2020, research from the U.S. had shown that white-tailed deer were being infected with SARS-CoV-2,…
-
Thermo Fisher Scientific and Innoforce established biologics and steriles drug manufacturing facility in China
On Nov. 6, 2020, Thermo Fisher Scientific and Innoforce announced a joint venture agreement to establish a new…
-
FDA authorized first test that detected neutralizing antibodies from recent or prior SARS-CoV-2 infection
On Nov. 6, 2020, the FDA authorized the first serology test that detected neutralizing antibodies from recent or…
-
Single-cell study of Ebola highlighted virus’s lethal maneuvers
On Nov. 6, 2020, in a study published in Cell, the researchers identified antiviral defense genes that the…
-
Mesa Biotech received additional $13 million from HHS to develop 30 minute SARS-CoV-2 & Flu A/Flu B test
On Nov. 6, 2020, Mesa Biotech announced it had been awarded a contract up to $13 million from…
-
RECOVERY trial DMC recommended continuing evaluation of REGN-COV2 in hospitalized patients
On Nov. 5, 2020, Regeneron announced an update from the independent data monitoring committee (DMC) for the UK-based…
-
Denmark tightened lockdown in north, mink cull devastates industry
On Nov. 5, 2020, Denmark announced strict lockdown rules in the north of the country after authorities discovered…
-
Novartis’ randomized, double-blind, placebo-controlled CAN-COVID trial failed to meet endpoints
On Nov. 5, 2020, Novartis announced data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial…
-
Neoleukin Therapeutics announced publication of de novo protein decoys that block COVID-19 infection
On Nov. 5, 2020, Neoleukin Therapeutics announced the publication in Science of research describing novel molecules designed to…
